Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Celltrion, Inc. Issues FY 2013 Outlook Below Analysts' Estimates
Celltrion, Inc. announced that it expects its fiscal year 2013 revenue, operating profit and net profit to record KRW 510.4 billion, KRW 269 billion and KRW 215.6 billion. According to According to I/B/E/S, analysts on average are expecting the Company to report revenue and net profit of KRW 519.87 billion and KRW 266.14 billion for fiscal year 2013.
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters